Relmada Therapeutics Inc (RLMD) Stock Price, Quote & News

Company Profile

Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessiv...

Industry: Biotechnology

Sector: Healthcare

Phone: 786 629 1376

Website: www.relmada.com

Address:

2222 Ponce de Leon Blvd., Floor 3, Coral Gables, United States

stoxx0007 Dec. 25 at 3:42 AM

$RLMD = Awesome year for RLMD 👏

0 · Reply

signaljumper Dec. 24 at 4:04 PM

$RLMD ready fir Breakout and build next Leg Up

0 · Reply

TheInside2028 Dec. 24 at 9:10 AM

$RLMD great consolidation and range/consolidation..this is a winner

0 · Reply

JarvisFlow Dec. 22 at 12:19 PM

Jefferies updates rating for Relmada Therapeutics ( $RLMD ) to Buy, target set at 9.

0 · Reply

notreload_ai Dec. 22 at 10:52 AM

Jefferies and BTIG start coverage on $RLMD and $IVVD with Buy ratings, citing pipeline shifts, strong assets, and large market potential. https://notreload.xyz/jefferies-backs-relmada-btig-turns-bullish-on-invivyd/

0 · Reply

teaman60 Dec. 20 at 2:43 AM

$RLMD insider buying, I like it

1 · Reply

MoonDrinker0 Dec. 20 at 1:47 AM

$RLMD

0 · Reply

misterbond007 Dec. 19 at 4:13 AM

$RLMD

0 · Reply

StockConsultant Dec. 17 at 1:42 PM

$RLMD Relmada Therapeutics stock, watch for a narrow range breakout

0 · Reply

signaljumper Dec. 17 at 9:44 AM

$RLMD sonder bought again https://www.sec.gov/Archives/edgar/data/1553643/000121390025121974/xslF345X05/ownership.xml

0 · Reply

Relmada Therapeutics Announces Presentation of NDV-01 Phase 2 Data at the Society for Urologic Oncology

Nov 13, 2025, 7:21 PM EST - 5 weeks ago

Relmada Therapeutics, Inc. (RLMD) Q3 2025 Earnings Call Transcript

Nov 13, 2025, 4:01 PM EST - 5 weeks ago

Relmada Therapeutics Reports Third Quarter 2025 Financial Results and Provides Key Clinical, Regulatory, and Corporate Updates

Nov 7, 2025, 7:30 AM EST - 6 weeks ago

Relmada Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 13, 2025

Nov 4, 2025, 7:09 AM EST - 7 weeks ago

Relmada Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Nov 4, 2025, 7:01 AM EST - 7 weeks ago

Relmada Announces FDA Feedback Supporting 2 Separate Acceptable Registrational Study Paths for NDV-01 in Non-muscle Invasive Bladder Cancer

Oct 7, 2025, 7:30 AM EDT - 2 months ago

Relmada Therapeutics Appoints Distinguished Urologic Oncologist, Max Kates, MD, to the Clinical Advisory Board to Support Development of NDV-01

Sep 16, 2025, 9:00 AM EDT - 3 months ago

Relmada Regains Compliance with Nasdaq Minimum Bid Price Requirement

Sep 10, 2025, 7:15 AM EDT - 3 months ago

Relmada Issues Mid-Year CEO Letter to Shareholders

Aug 8, 2025, 1:55 PM EDT - 4 months ago

Relmada Therapeutics, Inc. (RLMD) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 4:05 PM EDT - 4 months ago

Relmada Therapeutics Reports Second Quarter 2025 Financial Results and Announces NDV-01 6-Month Follow-up Safety and Efficacy Data in NMIBC

Jul 31, 2025, 7:00 AM EDT - 5 months ago

Relmada Therapeutics to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025

Jul 15, 2025, 8:00 AM EDT - 5 months ago

Relmada Therapeutics Appoints Renowned Urologic Oncologist, Yair Lotan, MD, to Chair the Clinical Advisory Board and Support Development of NDV-01

Jul 9, 2025, 8:00 AM EDT - 6 months ago

DIMERx Appoints Biotech Leader Sergio Traversa, PharmD, to Board of Directors

Jun 17, 2025, 7:00 AM EDT - 6 months ago

Relmada Therapeutics Appoints Urology Expert Raj S. Pruthi, MD as CMO-Urology

May 12, 2025, 10:02 PM EDT - 8 months ago

Relmada Therapeutics, Inc. (RLMD) Q1 2025 Earnings Call Transcript

May 12, 2025, 4:01 PM EDT - 8 months ago

Relmada Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 8, 2025, 7:30 AM EDT - 8 months ago

Relmada Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025

Apr 28, 2025, 1:38 PM EDT - 8 months ago

Relmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Data at AUA2025

Apr 27, 2025, 9:00 AM EDT - 8 months ago

UPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025

Apr 24, 2025, 8:00 AM EDT - 8 months ago

Relmada Therapeutics to Host KOL Event on Phase 2 NDV-01 Data

Apr 14, 2025, 7:30 AM EDT - 9 months ago

Relmada Therapeutics To Present NDV-01 Data at AUA2025

Mar 27, 2025, 8:07 PM EDT - 9 months ago

Relmada Therapeutics, Inc. (RLMD) Q4 2024 Earnings Call Transcript

Mar 27, 2025, 4:05 PM EDT - 9 months ago

Relmada Therapeutics Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update

Mar 26, 2025, 9:00 AM EDT - 9 months ago

Relmada Therapeutics to Report Fourth Quarter 2024 Financial Results on Thursday, March 27, 2025

Mar 25, 2025, 7:30 AM EDT - 9 months ago

Relmada Therapeutics Licenses Phase 2 Bladder Cancer Candidate, NDV-01, from Trigone Pharma, Ltd.

Feb 6, 2025, 7:30 AM EST - 11 months ago

Relmada Therapeutics Acquires Potential Therapy for Tourette Syndrome from Asarina Pharma AB

Dec 9, 2024, 8:11 AM EST - 1 year ago

Relmada discontinues late-stage trials for depression drug, explores sale

Dec 9, 2024, 7:30 AM EST - 1 year ago

Relmada Therapeutics to Discontinue the Reliance II and Relight Phase 3 Studies of REL-1017

Dec 4, 2024, 2:02 PM EST - 1 year ago

Relmada Therapeutics Stock Plummets Losing 80% Value - Here's Why

Dec 4, 2024, 8:00 AM EST - 1 year ago

Relmada's depression drug unlikely to meet main trial goal, analysis shows

Dec 4, 2024, 7:30 AM EST - 1 year ago

Relmada Therapeutics Reports That Data Monitoring Committee (DMC) Assessment Indicates That the Phase 3 Reliance II Trial is Futile at its Interim Analysis and is Unlikely to Meet the Primary Efficacy Endpoint with Statistical Significance

Nov 21, 2024, 1:34 PM EST - 1 year ago

Kuehn Law Encourages Investors of Relmada Therapeutics, Inc. to Contact Law Firm

Nov 14, 2024, 7:30 AM EST - 1 year ago

Relmada Therapeutics Initiates Phase 1 Dosing with REL-P11 for Metabolic Disease

Nov 10, 2024, 9:39 AM EST - 1 year ago

Relmada Therapeutics, Inc. (RLMD) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 4:32 PM EST - 1 year ago

Relmada Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 4, 2024, 4:30 PM EST - 1 year ago

Relmada Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024

Aug 9, 2024, 6:25 AM EDT - 1 year ago

Relmada Therapeutics, Inc. (RLMD) Q2 2024 Earnings Call Transcript

Aug 7, 2024, 4:05 PM EDT - 1 year ago

Relmada Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 5, 2024, 7:30 AM EDT - 1 year ago

Relmada Therapeutics to Report Second Quarter 2024 Financial Results on August 7, 2024

Jul 30, 2024, 9:45 AM EDT - 1 year ago

Relmada Therapeutics Inc Investigated By The Schall Law Firm For Possible Securities Violations Impacted Investors Urged To Engage In Dialogue

Jul 23, 2024, 3:45 PM EDT - 1 year ago

Relmada Therapeutics Inc Investigated By The Schall Law Firm For Possible Securities Violations, Impacted Investors Urged To Engage In Dialogue

Jul 22, 2024, 11:00 PM EDT - 1 year ago

Relmada Therapeutics Inc Under Investigation By The Schall Law Firm For Possible Securities Violations Encourages Impacted Investors To Initiate Dialogue

Jul 19, 2024, 5:45 PM EDT - 1 year ago

Relmada Therapeutics Inc Is Under Investigation By The Schall Law Firm For Possible Securities Breaches And Impacted Investors Are Encouraged To Initiate Dialogues

Jul 18, 2024, 5:15 PM EDT - 1 year ago

The Schall Law Firm Is Investigating Relmada Therapeutics Inc For Potential Securities Violations And Urges Affected Investors To Start Conversations

Jul 17, 2024, 3:30 PM EDT - 1 year ago

Relmada Therapeutics Inc Is Under Examination For Possible Securities Breaches By The Schall Law Firm, Impacted Investors Are Encouraged To Initiate Dialogues

Jul 16, 2024, 3:45 PM EDT - 1 year ago

The Schall Law Firm Encourages Affected Investors To Start Conversation, Relmada Therapeutics Inc Is Under Scrutiny For Potential Securities Breaches

Jul 15, 2024, 3:15 PM EDT - 1 year ago

Relmada Therapeutics Inc Under Investigation By The Schall Law Firm For Possible Securities Violations Urging Impacted Investors To Initiate Dialogue

Jul 13, 2024, 7:00 PM EDT - 1 year ago

Relmada Therapeutics Inc Under Probe By The Schall Law Firm For Possible Securities Breaches Urges Affected Investors To Start Conversation

Jul 12, 2024, 6:45 PM EDT - 1 year ago

Potential Securities Violations By Relmada Therapeutics Inc Are Under Investigation By The Schall Law Firm Encouraging Impacted Investors To Initiate Dialogue

stoxx0007 Dec. 25 at 3:42 AM

$RLMD = Awesome year for RLMD 👏

0 · Reply

signaljumper Dec. 24 at 4:04 PM

$RLMD ready fir Breakout and build next Leg Up

0 · Reply

TheInside2028 Dec. 24 at 9:10 AM

$RLMD great consolidation and range/consolidation..this is a winner

0 · Reply

JarvisFlow Dec. 22 at 12:19 PM

Jefferies updates rating for Relmada Therapeutics ( $RLMD ) to Buy, target set at 9.

0 · Reply

notreload_ai Dec. 22 at 10:52 AM

0 · Reply

teaman60 Dec. 20 at 2:43 AM

$RLMD insider buying, I like it

1 · Reply

MoonDrinker0 Dec. 20 at 1:47 AM

$RLMD

0 · Reply

misterbond007 Dec. 19 at 4:13 AM

$RLMD

0 · Reply

StockConsultant Dec. 17 at 1:42 PM

$RLMD Relmada Therapeutics stock, watch for a narrow range breakout

0 · Reply

signaljumper Dec. 17 at 9:44 AM

$RLMD sonder bought again https://www.sec.gov/Archives/edgar/data/1553643/000121390025121974/xslF345X05/ownership.xml

0 · Reply

Doozio Dec. 17 at 2:42 AM

$RLMD Whut 🐑 correction ENTA 🐒🍌🧠⏰♾️

0 · Reply

CEOBuysDisclosures Dec. 16 at 4:35 PM

$RLMD CEO purchased 27,500 shares at $4.12 for a total of $113,300. TRAVERSA SERGIO now owns 1,300,000 shares. https://ceo-buys.com

0 · Reply

Caveman25 Dec. 16 at 4:27 PM

$RLMD CEO Sergio Traversa buys 27,500 shares at $4.12 for a total value of $113,300, a sign of confidence from management in the stock I know it RLMD doesn't stand for Real Madrid 😂 Watch and learn $GRI 😂

0 · Reply

Vegas1 Dec. 16 at 3:18 PM

$RLMD solid swing set up ready for 5.01/8.00+ over the day and 8/21 on weekly swing in play

0 · Reply

DARKP00L Dec. 16 at 2:40 PM

$RLMD 09:33 on Dec. 16 2025 Relmada Therapeutics Form4 Filing Shows CEO Sergio Traversa Bought 1,225,500 Shares At An Average Price Of $0.09/Share #tradeideas

0 · Reply

DARKP00L Dec. 16 at 2:34 PM

$RLMD 09:33 on Dec. 16 2025 Relmada Therapeutics Form4 Filing Shows CEO Sergio Traversa Bought 1,225,500 Shares At An Average Price Of $0.09/Share #tradeideas

0 · Reply

SuperGreenToday Dec. 16 at 9:33 AM

$RLMD Share Price: $4.36 Contract Selected: May 15, 2026 $5 Calls Buy Zone: $0.84 – $1.04 Target Zone: $1.35 – $1.65 Potential Upside: 52% ROI Time to Expiration: 149 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

ZRadly Dec. 16 at 3:44 AM

$RLMD Good roller-coaster 😉

0 · Reply

TheInside2028 Dec. 15 at 9:15 PM

$RLMD this is a pressure cooker! Gonna go. Patience is a virtue!

0 · Reply

stoxx0007 Dec. 9 at 9:09 PM

$RLMD = sneaky one here! 👏👏😁

0 · Reply

signaljumper Dec. 9 at 3:37 PM

$RLMD a Close above 4.56 and we are again of the Race tothe next Targets 5$ , 5.57, 5.93 7.91$ is the main key than we are ready to fill the gap

1 · Reply

Wilburbeast69 Dec. 5 at 4:38 PM

$RLMD Brewing

0 · Reply

Market Cap	329.27M
Revenue (ttm)	0.00
Net Income (ttm)	-79.98M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	335,300
Avg Vol	1,313,278
Day's Range	N/A - N/A
Shares Out	73.33M
Stochastic %K	77%
Beta	0.74
Analysts	Strong Sell
Price Target	$6.67